- Home
- ATRA vs APLT Comparison
ATRA vs APLT Comparison
Compare ATRA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- APLT
- Stock Information
- Founded
- ATRA 2012
- APLT 2016
- Country
- ATRA United States
- APLT United States
- Employees
- ATRA N/A
- APLT N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ATRA Health Care
- APLT Health Care
- Exchange
- ATRA Nasdaq
- APLT Nasdaq
- Market Cap
- ATRA 67.9M
- APLT 69.0M
- IPO Year
- ATRA 2014
- APLT 2019
- Fundamental
- Price
- ATRA $12.18
- APLT $0.44
- Analyst Decision
- ATRA Strong Buy
- APLT Buy
- Analyst Count
- ATRA 3
- APLT 6
- Target Price
- ATRA $21.00
- APLT $6.10
- AVG Volume (30 Days)
- ATRA 59.4K
- APLT 877.5K
- Earning Date
- ATRA 08-11-2025
- APLT 11-06-2025
- Dividend Yield
- ATRA N/A
- APLT N/A
- EPS Growth
- ATRA N/A
- APLT N/A
- EPS
- ATRA 0.56
- APLT N/A
- Revenue
- ATRA $188,667,000.00
- APLT $121,000.00
- Revenue This Year
- ATRA N/A
- APLT N/A
- Revenue Next Year
- ATRA N/A
- APLT $5,931.24
- P/E Ratio
- ATRA $21.89
- APLT N/A
- Revenue Growth
- ATRA 202.41
- APLT N/A
- 52 Week Low
- ATRA $5.01
- APLT $0.30
- 52 Week High
- ATRA $18.71
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ATRA 53.50
- APLT 42.40
- Support Level
- ATRA $11.70
- APLT $0.46
- Resistance Level
- ATRA $13.20
- APLT $0.53
- Average True Range (ATR)
- ATRA 0.73
- APLT 0.03
- MACD
- ATRA -0.03
- APLT -0.01
- Stochastic Oscillator
- ATRA 47.96
- APLT 0.00
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.